Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical Models of Rare Corneal and Ocular Surface Diseases: a Comprehensive Narrative Review.

Ophthalmology and therapy·2026
Same author

The Role of Innervation in Ocular Surface Homeostasis, Tissue Remodeling Following Nerve Injury, and the Therapeutic Potential of Hemocomponents in Neuronal and Cicatricial Pathologies.

Journal of clinical medicine·2026
Same author

The Impact of Aging and Sex on Corneal Nerve Density and Function.

Investigative ophthalmology & visual science·2026
Same author

Congenital aniridia: European COST action ANIRIDIA-NET guidelines for diagnosis, management and care.

Acta ophthalmologica·2025
Same author

Keratoconus: The Local Manifestation of a Systemic Disease?

Journal of clinical medicine·2025
Same author

The Effects of Vitamin D on Keratoconus Progression.

American journal of ophthalmology·2025

Related Experiment Video

Updated: Jul 13, 2026

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

Targeting amyloid-beta in glaucoma treatment.

Li Guo1, Thomas E Salt, Vy Luong

  • 1Glaucoma and Retinal Degeneration Research, University College London Institute of Ophthalmology, Bath Street, London EC1V 9EL, United Kingdom.

Proceedings of the National Academy of Sciences of the United States of America
|August 9, 2007
PubMed
Summary

Alzheimer's disease mechanisms, including amyloid-beta (Abeta) deposition and cell death, are implicated in glaucoma. Targeting Abeta pathways shows promise for treating glaucoma and preventing blindness.

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Related Experiment Videos

Last Updated: Jul 13, 2026

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Molecular Biology

Background:

  • Glaucoma is a leading cause of irreversible blindness, traditionally linked to intraocular pressure.
  • Alzheimer's disease involves amyloid-beta (Abeta) deposition, neuronal apoptosis, and cell loss.

Purpose of the Study:

  • To investigate the role of Abeta in glaucoma pathogenesis.
  • To evaluate therapeutic strategies targeting the Abeta pathway for glaucoma.

Main Methods:

  • Examined Abeta colocalization with apoptotic retinal ganglion cells (RGCs) in experimental glaucoma models.
  • Assessed the impact of Abeta on RGC apoptosis in vivo.
  • Tested the efficacy of targeting Abeta formation and aggregation pathways, including combination therapies.

Main Results:

  • Abeta was found to colocalize with apoptotic RGCs in glaucoma.
  • Abeta induced RGC apoptosis in a dose- and time-dependent manner.
  • Targeting Abeta pathways reduced glaucomatous RGC apoptosis, with triple therapy being more effective than monotherapy.

Conclusions:

  • Abeta pathway targeting represents a novel therapeutic strategy for glaucoma management.
  • Combination therapy is potentially the most effective approach for Abeta-related diseases like glaucoma.